The effect of pre-transplant JAK 1/2 inhibitors on outcomes of myelofibrosis patients who receive allogeneic stem cell transplant

At the 2018 ASCO Annual Meeting, researchers presented the results of their retrospective analysis, showing that patients with intermediate-risk myelofibrosis who received JAK1/2 inhibitor therapy before undergoing hematopoietic stem cell transplant (SCT) had better survival outcomes than those who did not receive SCT.

 Journal of Clinical Oncology (ASCO Abstract)

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.